Arialys Therapeutics Website, Blog & Press Pages

Arialys Therapeutics Website, Blog & Press Pages - aVenture Research

Library

arialysrx.comCrawled Oct 14, 2026

Press

4 pages

February 26, 2025Press ReleasesArialys Therapeutics Initiates MAD Cohorts Having Completed All Planned SAD Cohorts in a Phase 1 Study of ART5803 for the Treatment of Autoimmune Neuropsychiatric Disease/news/arialys-therapeutics-initiates-mad-cohorts-having-completed-all-planned-sad-cohorts-in-a-phase-1-study-of-art5803-for-the-treatment-of-autoimmune-neuropsychiatric-disease
June 15, 2026Press ReleasesArialys Therapeutics Announces First ANRE Patient Treated with ART5803 in Open-Label Phase 2 Study and FDA Clearance of IND for Randomized Phase 2 Study/news/arialys-therapeutics-announces-first-anre-patient-treated-with-art5803-in-open-label-phase-2-study-and-fda-clearance-of-ind-for-randomized-phase-2-study
News/news
Arialys Therapeutics News & Events
September 25, 2025Press ReleasesArialys Therapeutics Receives FDA Rare Pediatric Disease Designation for ART5803 to Treat Anti-NMDA Receptor Encephalitis/news/arialys-therapeutics-receives-fda-rare-pediatric-disease-designation-for-art5803-to-treat-anti-nmda-receptor-encephalitis

Careers & Hiring

1 page

Careers/careers
Arialys is exploring scientific breakthroughs to develop new precision medicines for autoimmune neuropsychiatric diseases.

Team

1 page

Team/team
Arialys Therapeutics, a private biotech company founded by Avalon BioVentures with Catalys Pacific and MPM Capital

Contact

1 page

Contact/contact
Contact Arialys Therapeutics

Homepage

1 page

Homepage/
The company explores therapeutic opportunities for people with autoimmune neuropsychiatric diseases.

Privacy

1 page

Coverage

5 items

Arialys Therapeutics Announces U.S. FDA Fast Track Designation for ART5803, the First Precision Therapeutic Candidate in Development for the Treatment of Anti-NMDA Receptor Encephalitisbiospace.com/press-releases/arialys-therapeutics-announces-u-s-fda-fast-track-designation-for-art5803-the-first-precision-therapeutic-candidate-in-development-for-the-treatment-of-anti-nmda-receptor-encephalitis
Arialys Therapeutics secures U.S. FDA Fast Track designation for **ART5803**, its first precision therapy targeting **anti-NMDA receptor encephalitis (ANRE)**. The company develops autoimmune neuropsychiatric disease treatments, and ART5803 uses structural biology to block autoantibodies driving ANRE pathology. This designation accelerates clinical development for a rare, severe neurological disorder with limited treatment options.
Jul 2026BioSpaceNews article
Study supports monovalent antibody in neuropsychiatric diseaseddw-online.com/study-supports-monovalent-antibody-in-neuropsychiatric-disease-35391-202506/
Arialys Therapeutics’ drug candidate **ART5803** blocks the disease mechanism in **anti-NMDA receptor encephalitis (ANRE)** and reverses behavioral symptoms in non-human primates. Preclinical data show the monovalent antibody targets the underlying pathology linked to neuropsychiatric disorders. The findings highlight ART5803’s potential as a therapeutic intervention for ANRE-related symptoms.
Jun 2025Drug Discovery World (DDW)News article
Arialys' precision therapy shows promise in rare encephalitis disorder and beyondfiercebiotech.com/research/arialys-therapeutics-precision-therapy-shows-promise-rare-encephalitis-disorder-and-beyond
Arialys Therapeutics demonstrates preclinical efficacy for a precision therapy targeting the root cause of **anti-NMDA receptor encephalitis (ANRE)**, a rare neurological disorder linked to severe psychiatric and neurological symptoms. The approach focuses on addressing the disorder’s underlying pathology rather than symptoms alone. Early results suggest potential applications beyond ANRE, though clinical validation remains pending.
Jun 2025Fierce BiotechNews article
Arialys Launches with $58 Million to Develop Precision Medicines for Autoimmune Neuropsychiatric Diseasesglobalgenes.org/raredaily/arialys-launches-with-58-million-to-develop-precision-medicines-for-autoimmune-neuropsychiatric-diseases/
Arialys Therapeutics secures **$58 million in seed funding** to advance precision medicines targeting autoimmune neuropsychiatric disorders. The company focuses on developing novel therapeutics for conditions at the intersection of autoimmunity and neuropsychiatry. This financing supports early-stage research and drug development in a high-unmet-need area.
Sep 2023Global GenesNews article